Larimar Therapeutics (LRMR) Competitors $4.24 +0.34 (+8.72%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$4.28 +0.04 (+1.06%) As of 08:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LRMR vs. GPCR, HRMY, PAHC, SDGR, AUPH, AVDL, JANX, EVO, RCUS, and STOKShould you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include Structure Therapeutics (GPCR), Harmony Biosciences (HRMY), Phibro Animal Health (PAHC), Schrodinger (SDGR), Aurinia Pharmaceuticals (AUPH), Avadel Pharmaceuticals (AVDL), Janux Therapeutics (JANX), Evotec (EVO), Arcus Biosciences (RCUS), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry. Larimar Therapeutics vs. Its Competitors Structure Therapeutics Harmony Biosciences Phibro Animal Health Schrodinger Aurinia Pharmaceuticals Avadel Pharmaceuticals Janux Therapeutics Evotec Arcus Biosciences Stoke Therapeutics Larimar Therapeutics (NASDAQ:LRMR) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations. Do insiders and institutionals believe in LRMR or GPCR? 91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by insiders. Comparatively, 5.6% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, LRMR or GPCR? Structure Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLarimar TherapeuticsN/AN/A-$80.60M-$1.56-2.72Structure TherapeuticsN/AN/A-$122.53M-$1.05-27.84 Which has more risk and volatility, LRMR or GPCR? Larimar Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Structure Therapeutics has a beta of -1.65, indicating that its share price is 265% less volatile than the S&P 500. Do analysts prefer LRMR or GPCR? Larimar Therapeutics presently has a consensus target price of $16.71, indicating a potential upside of 294.20%. Structure Therapeutics has a consensus target price of $68.67, indicating a potential upside of 134.92%. Given Larimar Therapeutics' higher possible upside, analysts plainly believe Larimar Therapeutics is more favorable than Structure Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80Structure Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Is LRMR or GPCR more profitable? Structure Therapeutics' return on equity of -21.31% beat Larimar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Larimar TherapeuticsN/A -62.92% -53.98% Structure Therapeutics N/A -21.31%-20.34% Does the media refer more to LRMR or GPCR? In the previous week, Larimar Therapeutics had 2 more articles in the media than Structure Therapeutics. MarketBeat recorded 9 mentions for Larimar Therapeutics and 7 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.04 beat Larimar Therapeutics' score of 0.53 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryLarimar Therapeutics and Structure Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LRMR vs. The Competition Export to ExcelMetricLarimar TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$322.83M$2.96B$6.12B$10.45BDividend YieldN/A57.77%5.73%4.78%P/E Ratio-2.7222.7985.3827.36Price / SalesN/A778.16602.69196.46Price / CashN/A172.6337.4661.86Price / Book1.585.5112.516.81Net Income-$80.60M$33.06M$3.32B$276.80M7 Day Performance-6.81%0.23%0.60%0.42%1 Month Performance6.00%14.73%10.53%7.86%1 Year Performance-45.01%-1.42%74.30%41.24% Larimar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LRMRLarimar Therapeutics2.968 of 5 stars$4.24+8.7%$16.71+294.2%-42.9%$322.83MN/A-2.7230News CoverageGPCRStructure Therapeutics3.2108 of 5 stars$28.68+5.1%$68.67+139.4%-19.5%$1.57BN/A-27.31136Positive NewsHRMYHarmony Biosciences4.7068 of 5 stars$26.59-2.5%$45.50+71.1%-25.0%$1.57B$714.73M8.58200Analyst ForecastPAHCPhibro Animal Health4.2984 of 5 stars$37.79-1.4%$28.40-24.8%+62.1%$1.55B$1.30B32.032,475Analyst ForecastSDGRSchrodinger2.6295 of 5 stars$21.29+3.4%$26.57+24.8%+16.8%$1.52B$207.54M-8.58790Analyst ForecastGap UpAUPHAurinia Pharmaceuticals3.0058 of 5 stars$11.32-0.3%$13.00+14.8%+59.3%$1.49B$235.13M26.33300AVDLAvadel Pharmaceuticals2.7517 of 5 stars$14.53-3.2%$20.86+43.5%+14.8%$1.46B$169.12M-484.3370JANXJanux Therapeutics2.1364 of 5 stars$22.76-5.2%$78.31+244.1%-46.4%$1.44B$10.59M-12.6430EVOEvotec2.0051 of 5 stars$3.99-0.5%$5.40+35.3%+35.5%$1.42B$862.40M0.004,827RCUSArcus Biosciences1.9913 of 5 stars$14.54+8.9%$21.14+45.4%-5.2%$1.42B$258M-4.59500Analyst ForecastHigh Trading VolumeSTOKStoke Therapeutics3.0271 of 5 stars$26.81+4.9%$25.57-4.6%+180.5%$1.40B$36.56M31.54100Analyst Forecast Related Companies and Tools Related Companies Structure Therapeutics Alternatives Harmony Biosciences Alternatives Phibro Animal Health Alternatives Schrodinger Alternatives Aurinia Pharmaceuticals Alternatives Avadel Pharmaceuticals Alternatives Janux Therapeutics Alternatives Evotec Alternatives Arcus Biosciences Alternatives Stoke Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LRMR) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
